EnliTISA

EnliTISA is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and fibrotic diseases with significant unmet medical needs. Founded by a Sino-Swedish team including Nobel Laureate Professor Bengt Samuelsson, the company leverages its expertise in multi-pathway immunomodulation to create treatments that are safer and more effective than traditional steroids. Its lead candidate, TISA-818 (UP-818), is currently in Phase II clinical development for Acute Respiratory Distress Syndrome (ARDS) and has demonstrated promising results in studies for Idiopathic Pulmonary Fibrosis (IPF) and radiation-induced oral mucositis. EnliTISA follows a strategic out-licensing business model, exemplified by its multiple partnerships with Shanghai Pharma for the Chinese market. The company is headquartered in Shanghai's Pudong New District and maintains active clinical research operations in both China and Europe.